Radiation sensitivity of human squamous cell carcinoma cells in vitro is modulated by all-trans and 13-cis-retinoic acid in combination with interferon-alpha

Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):991-8. doi: 10.1016/s0360-3016(99)00298-9.

Abstract

Purpose: Retinoids and interferon-alpha (IFN-alpha) have been shown to exert antiproliferative and radiosensitizing effects. The present study was designed to determine differential effects of retinoids in combination with IFN-alpha on radiation toxicity of 5 human squamous cell carcinoma (SCC) cell lines.

Methods and materials: Using clonogenic assays, the effects of all-trans (ATRA), 13-cis-retinoic acid (13cRA), and IFN-alpha on radiation toxicity were analyzed. Basal mRNA expression of the cytoplasmic retinoic acid binding protein, CRABP I, was determined in retinoid-sensitive and -insensitive cell lines by reverse transcriptase/polymerase chain reaction (RT-PCR).

Results: Treatment with ATRA, 13cRA, or IFN-alpha resulted in a cell line-specific inhibition of clonogenic survival. A comparison of retinoid-sensitive and insensitive cells revealed that retinoid sensitivity seems to be dependent on the basal expression level of CRABP I. ATRA, 13cRA, and IFN-alpha alone or in combination altered radiation sensitivity by affecting predominantly the alpha-component of the linear-quadratic dose-response curve. Likewise, depending upon the treatment condition the surviving fraction at 2 Gy (SF2) was decreased cell line-specifically. Combined treatment with ATRA or 13cRA and IFN-alpha markedly enhanced radiation cytotoxicity.

Conclusion: These in vitro data indicate that the combined treatment with retinoids, IFN-alpha, and ionizing radiation could be beneficial for patients presenting with SCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / metabolism
  • Carcinoma, Squamous Cell / radiotherapy*
  • Combined Modality Therapy
  • Dose Fractionation, Radiation
  • Dose-Response Relationship, Radiation
  • Humans
  • Interferon-alpha / administration & dosage
  • Isotretinoin / administration & dosage
  • Neoplasm Proteins / metabolism
  • Radiation Tolerance
  • Radiation-Sensitizing Agents / therapeutic use*
  • Receptors, Retinoic Acid / metabolism
  • Tretinoin / administration & dosage
  • Tumor Cells, Cultured

Substances

  • Interferon-alpha
  • Neoplasm Proteins
  • Radiation-Sensitizing Agents
  • Receptors, Retinoic Acid
  • retinoic acid binding protein I, cellular
  • Tretinoin
  • Isotretinoin